Logo image of GELS

GELTEQ LTD (GELS) Stock Fundamental Analysis

NASDAQ:GELS - Nasdaq - AU0000218109 - Common Stock - Currency: USD

1.91  +0.23 (+13.69%)

After market: 1.86 -0.05 (-2.62%)

Fundamental Rating

1

Overall GELS gets a fundamental rating of 1 out of 10. We evaluated GELS against 198 industry peers in the Pharmaceuticals industry. GELS has a bad profitability rating. Also its financial health evaluation is rather negative. GELS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year GELS has reported negative net income.
In the past year GELS has reported a negative cash flow from operations.
GELS Yearly Net Income VS EBIT VS OCF VS FCFGELS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -1M -2M -3M

1.2 Ratios

GELS has a Return On Assets of -17.08%. This is in the better half of the industry: GELS outperforms 64.65% of its industry peers.
GELS's Return On Equity of -23.47% is fine compared to the rest of the industry. GELS outperforms 67.68% of its industry peers.
Industry RankSector Rank
ROA -17.08%
ROE -23.47%
ROIC N/A
ROA(3y)-15.69%
ROA(5y)N/A
ROE(3y)-19.47%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GELS Yearly ROA, ROE, ROICGELS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -5 -10 -15 -20

1.3 Margins

GELS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GELS Yearly Profit, Operating, Gross MarginsGELS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

1

2. Health

2.1 Basic Checks

GELS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GELS remains at a similar level compared to 1 year ago.
GELS has a worse debt/assets ratio than last year.
GELS Yearly Shares OutstandingGELS Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2M 4M 6M 8M
GELS Yearly Total Debt VS Total AssetsGELS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of 1.23, we must say that GELS is in the distress zone and has some risk of bankruptcy.
GELS has a Altman-Z score of 1.23. This is in the better half of the industry: GELS outperforms 64.65% of its industry peers.
A Debt/Equity ratio of 0.12 indicates that GELS is not too dependend on debt financing.
The Debt to Equity ratio of GELS (0.12) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Altman-Z 1.23
ROIC/WACCN/A
WACC9.48%
GELS Yearly LT Debt VS Equity VS FCFGELS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 5M 10M 15M 20M

2.3 Liquidity

A Current Ratio of 0.08 indicates that GELS may have some problems paying its short term obligations.
GELS's Current ratio of 0.08 is on the low side compared to the rest of the industry. GELS is outperformed by 96.46% of its industry peers.
GELS has a Quick Ratio of 0.08. This is a bad value and indicates that GELS is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of GELS (0.08) is worse than 96.46% of its industry peers.
Industry RankSector Rank
Current Ratio 0.08
Quick Ratio 0.08
GELS Yearly Current Assets VS Current LiabilitesGELS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 1M 2M 3M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for GELS have decreased by -1.13% in the last year.
GELS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-1.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.62%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GELS Yearly Revenue VS EstimatesGELS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 50K 100K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GELS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GELS Price Earnings VS Forward Price EarningsGELS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GELS Per share dataGELS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

GELS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GELTEQ LTD

NASDAQ:GELS (5/16/2025, 6:53:10 PM)

After market: 1.86 -0.05 (-2.62%)

1.91

+0.23 (+13.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.86%
Inst Owner ChangeN/A
Ins Owners48.88%
Ins Owner ChangeN/A
Market Cap18.03M
AnalystsN/A
Price TargetN/A
Short Float %1.63%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.86
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.24
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0
BVpS1.03
TBVpS-0.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.08%
ROE -23.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-15.69%
ROA(5y)N/A
ROE(3y)-19.47%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.08
Quick Ratio 0.08
Altman-Z 1.23
F-Score2
WACC9.48%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.62%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.53%
OCF growth 3YN/A
OCF growth 5YN/A